When does Soliqua’s patent expire?
Soliqua (insulin glargine/lixisenatide) is a combination product, so “Soliqua patent expiry” depends on which patent (or patent set) you mean—there isn’t a single, universal expiration date for the whole product. The relevant dates can vary by country and by whether you’re looking at an underlying active ingredient patent, a formulation/combination patent, or method-of-use patents.
The provided information doesn’t include any specific Soliqua patent numbers or jurisdictional expiry dates, so I can’t give a precise expiry date without more detail.
Which patents are usually involved in Soliqua exclusivity?
For branded combination drugs like Soliqua, exclusivity often rests on multiple layers, such as:
- Patents covering the combination (insulin glargine + lixisenatide) or specific formulations.
- Patents covering manufacturing, stability, or delivery devices.
- Method-of-use patents tied to dosing or patient populations.
Because these are different legal rights, the “last” one to expire is often the date people mean by “patent expiry,” but it may not match launch-level expectations unless you identify the specific patents.
How do you find the exact expiry date you care about (US vs EU/UK)?
To determine the exact date, you typically need:
- The country (most often the US, but also EU/UK/other markets).
- The drug’s brand and generic name.
- The specific patent(s) listed for that product in that jurisdiction (or the Orange Book / equivalent listing).
If you tell me the jurisdiction (e.g., “US”) and whether you mean patent expiry or regulatory exclusivity (and which one), I can narrow to the relevant set and give the correct date(s).
Patent expiry vs FDA exclusivity: what’s the difference for Soliqua?
Even after a patent expires, marketing may still be limited by regulatory exclusivity protections (for example, periods that can delay generic/biosimilar entry). Users searching “Soliqua patent expiry” sometimes mean “when can a generic/competitor launch,” which may be later than the first patent expiration.
What happens when Soliqua patents expire?
Once the key protections expire (and any exclusivity windows end), other companies can typically seek approval for products that rely on earlier science—often generics for the insulin component and competitors for the combination regimen—subject to safety, efficacy, and regulatory requirements, and any remaining litigation or other barriers.
If you share which market you mean (US, UK, EU, etc.), I can tailor the “what happens next” to the actual approval pathway used there.
Quick clarification so I can give the exact date
Reply with:
1) Which jurisdiction: US, EU, UK, or another country?
2) Do you mean patent expiry specifically, or “when generics/competitors can launch”?
With that, I can provide the precise expiration date(s) tied to Soliqua in that jurisdiction.